These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 31472049)
1. Clinical value of plasma cfDNA concentration and integrity in breast cancer patients. Miao Y; Fan Y; Zhang L; Ma T; Li R Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):64-72. PubMed ID: 31472049 [TBL] [Abstract][Full Text] [Related]
2. Serum cell-free DNA concentrations and integrity analysis of colorectal cancer patients before and after surgery. Cao G; Xie Y; Jiang X; Tian X; Wang D; Sun Y Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):44-51. PubMed ID: 31472046 [TBL] [Abstract][Full Text] [Related]
3. Analysis of serum cfDNA concentration and integrity before and after surgery in patients with lung cancer. Fan Y; Shi M; Chen S; Ju G; Chen L; Lu H; Chen J; Zheng S Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):56-63. PubMed ID: 31472048 [TBL] [Abstract][Full Text] [Related]
4. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse. Zhou H; Wang XJ; Jiang X; Qian Z; Chen T; Hu Y; Chen ZH; Gao Y; Wang R; Ye WW; Cao WM Breast Cancer Res Treat; 2019 Nov; 178(1):63-73. PubMed ID: 31364001 [TBL] [Abstract][Full Text] [Related]
5. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis. Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814 [TBL] [Abstract][Full Text] [Related]
6. Cell-free DNA as a biomarker for colorectal cancer: a retrospective analysis in patients before and after surgery. Zhong Y; Zhou Q; Zhang Y; Zhou S; Zhang G; Jiang C; Zhang Z; Zhang X; Xu J; Jin C; Cao L; Chen L Cell Mol Biol (Noisy-le-grand); 2020 May; 66(2):135-141. PubMed ID: 32415940 [TBL] [Abstract][Full Text] [Related]
7. Clinical significance of cell-free DNA concentration and integrity in serum of gastric cancer patients before and after surgery. Zhang X; Wu Z; Shen Q; Li R; Jiang X; Wu J; Li D; Wang D; Zou C; Zhong Y; Cheng X Cell Mol Biol (Noisy-le-grand); 2019 Sep; 65(7):111-117. PubMed ID: 31880527 [TBL] [Abstract][Full Text] [Related]
8. Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer. Hussein NA; Mohamed SN; Ahmed MA Appl Biochem Biotechnol; 2019 Mar; 187(3):1028-1045. PubMed ID: 30151636 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3. Tang Z; Li L; Shen L; Shen X; Ju S; Cong H Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836 [TBL] [Abstract][Full Text] [Related]
10. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer. Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881 [TBL] [Abstract][Full Text] [Related]
11. Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients: a pilot study. Giro C; Yamada AMTD; Cruz FJSM; do R Barros LA; da C A Alves B; Fonseca FLA; Del Giglio A Breast Cancer Res Treat; 2024 Jul; 206(2):329-335. PubMed ID: 38743176 [TBL] [Abstract][Full Text] [Related]
12. PUM1 and RNase P genes as potential cell-free DNA markers in breast cancer. Murillo Carrasco A; Acosta O; Ponce J; Cotrina J; Aguilar A; Araujo J; Rebaza P; Pinto JA; Fujita R; Buleje J J Clin Lab Anal; 2021 Apr; 35(4):e23720. PubMed ID: 33522650 [TBL] [Abstract][Full Text] [Related]
13. Promoter profiles in plasma CfDNA exhibits a potential utility of predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients. Yang X; Liu Q; Guo Z; Yang X; Li K; Han B; Zhang M; Sun M; Huang L; Cai G; Wu Y Breast Cancer Res; 2024 Jul; 26(1):112. PubMed ID: 38965610 [TBL] [Abstract][Full Text] [Related]
14. Aberrant reduction of telomere repetitive sequences in plasma cell-free DNA for early breast cancer detection. Wu X; Tanaka H Oncotarget; 2015 Oct; 6(30):29795-807. PubMed ID: 26356673 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of cfDNA and long fragment DNA in patients with breast cancer. Xu H; Liu G Cell Mol Biol (Noisy-le-grand); 2020 Oct; 66(7):186-189. PubMed ID: 33287940 [TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA in Egyptian women with breast Cancer: A marker for detection of primary cases and early prediction of recurrence. Gameel AM; Talaat RM; Sakr MA; Selim MA; Abo Alil DFA; Elkhouly EA Clin Chim Acta; 2024 Aug; 562():119878. PubMed ID: 39047884 [TBL] [Abstract][Full Text] [Related]
17. Investigation of Efficacy Evaluation Comparison of cfDNA and CEA in Colorectal Cancer. Yu D; An G; Xu L Clin Lab; 2016 Oct; 62(10):1947-1953. PubMed ID: 28164530 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic Value of Circulating Free DNA Integrity and Global Methylation Status in Gall Bladder Carcinoma. Kumari S; Husain N; Agarwal A; Neyaz A; Gupta S; Chaturvedi A; Lohani M; Sonkar AA Pathol Oncol Res; 2019 Jul; 25(3):925-936. PubMed ID: 29376201 [TBL] [Abstract][Full Text] [Related]
19. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer. Yang X; Zhang K; Zhang C; Peng R; Sun C BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027 [TBL] [Abstract][Full Text] [Related]
20. Cell-free DNA concentration and integrity as a screening tool for cancer. Zaher ER; Anwar MM; Kohail HM; El-Zoghby SM; Abo-El-Eneen MS Indian J Cancer; 2013; 50(3):175-83. PubMed ID: 24061455 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]